{"doi":"10.1016/j.jiac.2024.06.011","title":"Phase III, open-label, single-arm study of a new MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine dose in healthy Japanese children aged 5–6 years","abstract":null,"journal":"Journal of Infection and Chemotherapy","year":2024,"id":621813,"datarank":0.16479184330021646,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"self_citation_contribution":0.16479184330021646,"citation_network_contribution":0.0,"self_endowment_contribution":0.16479184330021646,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1605929,"name":"Asuka Kawamura","orcid":null,"position":1,"is_corresponding":false},{"id":1605930,"name":"Yoshitaka Sogawa","orcid":"0000-0003-1621-0929","position":2,"is_corresponding":false},{"id":1605931,"name":"Sachiko Sakakibara","orcid":null,"position":3,"is_corresponding":false},{"id":1605932,"name":"Takafumi Nakatsu","orcid":null,"position":4,"is_corresponding":false},{"id":1605933,"name":"Motoshi Kimata","orcid":null,"position":5,"is_corresponding":false},{"id":1605934,"name":"Keiji Oe","orcid":null,"position":6,"is_corresponding":false},{"id":3996,"name":"Tetsuo Nakayama","orcid":"0000-0002-8685-6007","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Phase III, open-label, single-arm study of a new MMR vaccine (JVC-001); measles AIK-C, mumps RIT 4385, rubella Takahashi, as a second vaccine dose in healthy Japanese children aged 5–6 years","abstract":"PURPOSE: This Phase III, multicenter, open-label, single-arm study evaluated the safety and immunogenicity of the measles-mumps-rubella (MMR) combined vaccine, JVC-001, as a second MMR vaccination. METHODS: Healthy Japanese children aged 5-6 years received a single dose of JVC-001 following a first measles, mumps, and rubella vaccination (measles-rubella bivalent and mumps monovalent vaccine [Hoshino or Torii strain] or JVC-001) or the MMR vaccine received between ages 1 to <4 years. Immunogenicity was evaluated using antibody titers before and after vaccination (Day 1/Day 43). The primary endpoint was the seroprotection rate of antibody titers against each virus; geometric mean titer (GMT) was also evaluated. Adverse events (AEs) and adverse drug reactions (ADRs) were monitored. RESULTS: One-hundred participants completed the study. The seroprotection rate of antibody titers against measles, rubella, and mumps virus (genotype D) were 100.0 % (95 % confidence interval [CI] 96.4 %, 100.0 %), 100.0 % (95 % CI 96.4 %, 100.0 %), and 100.0 % (95 % CI 96.3 %, 100.0 %), respectively. GMT (fold) increases (Day 1 to Day 43) were 16.0 to 55.7 for measles virus, 35.5 to 99.0 for rubella virus, and 25.7 to 89.5 for mumps virus (genotype D). Solicited ADRs occurred in 40.0 % of participants (injection site, 34.0 %; systemic, 13.0 %). CONCLUSIONS: The second MMR vaccination with JVC-001 demonstrated sufficient antibody coverage against all three viruses; the safety profile was tolerable. CLINICAL TRIAL REGISTRATION: jRCT2080225022.","is_dataset_classified":null,"base_score":1.0986122886681096,"endowment":1.0986122886681096,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38906375","pmcid":null,"openalex_id":"https://openalex.org/W4399803428","authors":[],"funders":[{"funder_name":"Daiichi Sankyo Co Ltd","grant_id":"","title":null}],"total_grants":1,"fwci":0.5657,"citation_percentile":0.66890529,"influential_citations":0,"citation_trend":[{"year":2025,"count":2}],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://www.jiac-j.com/article/S1341-321X(24)00166-1/pdf","host_type":"journal"},{"url":"https://www.jiac-j.com/article/S1341-321X(24)00166-1/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1341321X24001661?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1341321X24001661?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.jiac.2024.06.011","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38906375","host_type":"repository"}],"fields_of_study":["Virology and Viral Diseases","Immune responses and vaccinations","Vaccine Coverage and Hesitancy","Child","Child, Preschool","Female","Humans","Male","Antibodies, Viral","East Asian People","Immunization, Secondary","Immunogenicity, Vaccine","Japan","Measles","Measles-Mumps-Rubella Vaccine","Mumps","Rubella","Vaccination"],"mesh_terms":["Immunogenicity, Vaccine","East Asian People","Antibodies, Viral","Child","Child, Preschool","Female","Humans","Immunization, Secondary","Japan","Male","Measles","Measles virus","Mumps","Mumps virus","Rubella","Rubella virus","Vaccination","Measles-Mumps-Rubella Vaccine"],"keywords":["MMR vaccine","Measles-Mumps-Rubella Vaccine","Medicine","Measles","Rubella","Immunogenicity","Virology","Rubella vaccine","Mumps vaccine","Measles vaccine","Vaccination","Pediatrics","Immunology","Antigen","Neutralizing antibody","Rit 4385","Second Mmr Vaccination"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Zero hunger"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T16:10:57.159163Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}